GSK announces FDA granted BTD for Jemperli
GSK (GSK) announced that the US Food and Drug Administration, FDA, has granted Breakthrough Therapy Designation, BTD, for ...
Targeted Oncology1d
FDA Grants Dostarlimab Breakthrough Therapy Designation in dMMR/MSI-H Rectal Cancer
The FDA granted breakthrough therapy designation to dostarlimab for locally advanced dMMR/MSI-H rectal cancer, highlighting ...
Pharmabiz22h
US FDA grants breakthrough therapy designation to GSK’s Jemperli for locally advanced dMMR/MSI-H rectal cancer
GSK plc announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Jemperli (dostarlimab) for the treatment of patients with locally advanced mismatch ...
Caris Life Sciences Publishes Large-Scale Study Demonstrating the Critical Role of Next-Generation Sequencing in Microsatellite Instability Testing
Caris Life Sciences® (Caris), a leading next-generation AI TechBio company and precision medicine pioneer, today announced ...
Study finds increased survival with nivolumab plus ipilimumab vs. chemo for metastatic colorectal cancer
For patients with microsatellite-instability-high (MSI-H) or mismatch-repair-deficient (dMMR) metastatic colorectal cancer ...
Hosted on MSN19d
SELLAS announces data indicating key predictor of response to SLS009 in solid cancers
The results indicated that in CRC (colorectal carcinomas) with high-level microsatellite instability (MSI-H), ASXL1 ...
Too Old to Operate8d
Survival Up With Nivolumab + Ipilimumab Versus Chemo for Metastatic CRC
For patients with microsatellite-instability-high (MSI-H) or mismatch-repair-deficient (dMMR) metastatic colorectal cancer ...
The New England Journal of Medicine21d
Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer
Patients with microsatellite-instability–high (MSI-H) or mismatch-repair–deficient (dMMR) metastatic colorectal cancer have poor outcomes with standard chemotherapy with or without targeted ...
precisionmedicineonline1d
Ideaya Biosciences to Develop KAT6/7 Inhibitor in 8p11-Amplified Breast, Lung Cancers
NEW YORK – Ideaya Biosciences said on Monday that it plans to develop a KAT6/7 inhibitor, IDE251, as treatment for breast and lung cancer patients whose tumors harbor 8p11 amplifications.
Daily1d
Jemperli bags USFDA Breakthrough Therapy Designation for locally advanced dMMR/MSI-H rectal cancer: GSK
London: GSK plc has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for ...